Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14330 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Adi Shacham-Abulafia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Petah-Tikva, Israel. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome‐positive chronic‐phase chronic myeloid leukemia (CML‐CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation.
Methods
This retrospective analysis evaluated patients with CML treated with asciminib under a managed‐access program across eight Israeli centers from July 2019 to August 2022. We assessed treatment responses, toxicities, event‐free survival (EFS), and overall survival (OS) using Kaplan–Meier methods.
Results
The study included 30 patients who had received a median of three prior TKIs, with 73% starting asciminib due to intolerance. After a median follow‐up of 7.1 months, 85% of those without prior complete cytogenetic response (CCyR) achieved CCyR, and 60% previously not in major molecular response (MMR) attained MMR. Resistance was rare (10%), with no cardiovascular events reported despite high baseline comorbidity (73%). Median EFS was 47 months; median OS was not reached.
Conclusion
Asciminib demonstrates significant efficacy and tolerability in heavily pretreated patients with CML‐CP, with no new cardiovascular events observed. Further long‐term studies are necessary to explore its full cardiovascular impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Petah-Tikva, Israel.
- School of Medicine, Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
- Meir Medical Center, Hematology Institute, Kfar Saba, Israel.
- Hemato-Oncology Department, Assuta Medical Center, Tel Aviv, Israel.
- Hematology Institute, Soroka University Medical Center, Beer-Sheva, Israel.
ORCID-Profile: Adi Shacham-Abulafia
Zitieren
APA
Shacham-Abulafia, A., Volcheck, Y., Ellis, M., Shapira, S., Tavor, S., Gourevitch, A., Kreiniz, N., Stanevski, A., Raanani, P., & Koren-Michowitz, M. (2025). Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14330
Vancouver
Shacham-Abulafia A, Volcheck Y, Ellis M, Shapira S, Tavor S, Gourevitch A, et al. Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.14330
BibTeX
@article{ShachamAbulafia2025,
author = {Shacham-Abulafia, Adi and Volcheck, Yulia and Ellis, Martin and Shapira, Shirley and Tavor, Sigal and Gourevitch, Anna and Kreiniz, Natalia and Stanevski, Anfisa and Raanani, Pia and Koren-Michowitz, Maya},
title = {Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14330}
}
EUVIMED